Lupin Ltd — Board/Management Information 2024

May 6, 2024

==> picture [84 x 99] intentionally omitted <==

May 6, 2024

BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001.

 National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).

Re: Appointment of Independent Directors.

We are pleased to inform you that at its meeting held today i.e. May 6, 2024, the Board of Directors appointed Mr. Jeffrey Kindler (DIN: 10592395) and Mr. Alfonso Zulueta (DIN: 10597962), as Independent Directors of the Company effective May 6, 2024.

Disclosures in compliance with Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of appointment of Independent Directors are enclosed as Annexure - 'A’ .

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The Board meeting commenced at 2.30 p.m. (IST) and concluded at 8.30 p.m. (IST).

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan

Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2abcf74700f537 5b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb67a2ff09c42 42771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2024.05.06 20:46:28 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [84 x 99] intentionally omitted <==

Annexure - 'A ’

Particulars as per Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sl.No.	Particulars	Description
1.	reasons for change viz. appointment,re-appointment, resignation, removal,death or otherwise;	**i. **Appointment of Mr. Jeffrey Kindler (DIN: 10592395), asIndependent Director of the Company.**ii. **Appointment of Mr. Alfonso Zulueta (DIN: 10597962), asIndependent Director of the Company.
2.	dates of appointment/re-appointment/cessation & terms of appointment/re-appointment;	**i. **The appointment of Mr. Jeffrey Kindler is for a term of 5years, effective May 6, 2024.**ii. **The appointment of Mr. Alfonso Zulueta is for a term of 5years, effective May 6, 2024.
3.	brief profiles;	**i. **Mr. Jeffrey Kindler, 68, has completed a Bachelor of Artsdegree (Summa cum Laude) from Tufts University, USA anda Juris Doctor degree (Magna cum Laude) from HarvardLaw School, USA. He served as a law clerk to JusticeWilliam J. Brennan, Jr. of the United States Supreme Court.Mr. Kindler is an experienced healthcare executive,investor and advisor. He brings over four decades ofbusiness experience and has held leadership positions atsome of the world’s most recognized companiesincluding Pfizer, where he served as Chairman & ChiefExecutive Officer, as well as McDonald's Corporationand General Electric Company. Before that, he was apartner at the law firm of Williams & Connolly.Mr. Kindler is currently CEO of Centrexion Therapeutics, aprivately held biotechnology company, and a SeniorAdvisor to Blackstone. He has a deep understanding ofmultinational corporate matters including regulations,litigations, compliance, crisis management, brand,franchise management, executive leadership andmergers & acquisitions. Mr. Kindler is Chairman of theTalent&CompensationCommitteeofPerrigoPharmaceuticals; Chairman of the Audit Committee andMember of Compensation Committee of Precigen Inc.;Chairman of the Compensation Committee of TernsPharmaceuticals; and a member of the Audit andCompensation Committees of Jazz at Lincoln Center.**ii. **Mr. Alfonso Zuleta, 61, completed an Economicsundergraduate degree from De LA Salle University,Manila, where he was conferred the 2023 OutstandingAlumnusAward.HereceivedMBAdegreeinMarketing/FinancefromUniversity of Virginia, USA.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [84 x 99] intentionally omitted <==

Mr. Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, a global pharmaceutical company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company’s Executive Committee. Mr. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council.

Mr. Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Limited, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. He is also CEO/Owner of CZ Ventures, a company focused on start-up investments. Mr. Zulueta serves as a director of Glooko, Inc., a provider of connected care software solutions for persons with chronic conditions and of CTS Corporation, a leading global designer and manufacturer of sensors, actuators and electronic components. He previously served as a director of Amarin Corporation, Syneos Health, Inc. and Calidi Biotherapeutics, Inc.

Mr. Zulueta serves on a number of committees of boards including Audit, Compensation and ESG.

4. disclosure of relationships between directors

• i. Mr. Jeffrey Kindler is not related to any director on the Board of the Company.

ii. Mr. Alfonso Zulueta is not related to any director on the Board of the Company.

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2abcf74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2024.05.06 20:46:47 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com